Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
(2016) In PLoS ONE 11(3).- Abstract
- The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance. We hereby use metachronous contralateral breast cancer (CBC) developed despite prior adjuvant tamoxifen for the first tumor as an "in vivo"-model for tamoxifen resistance. AIB1-expression in the presumable resistant (CBC after prior tamoxifen) and naïve setting (CBC without prior tamoxifen) is compared and correlated to prognosis after CBC.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8852876
- author
- Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Ehinger, Anna LU ; Lövgren, Kristina LU ; Rydén, Lisa LU and Fernö, Mårten LU
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 11
- issue
- 3
- article number
- e0150977
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- pmid:26959415
- wos:000371992300089
- scopus:84962510005
- pmid:26959415
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0150977
- language
- English
- LU publication?
- yes
- id
- 0ae7472c-2886-48a3-b47a-722813f185ef (old id 8852876)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26959415?dopt=Abstract
- date added to LUP
- 2016-04-04 09:39:45
- date last changed
- 2022-04-23 21:38:56
@article{0ae7472c-2886-48a3-b47a-722813f185ef, abstract = {{The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance. We hereby use metachronous contralateral breast cancer (CBC) developed despite prior adjuvant tamoxifen for the first tumor as an "in vivo"-model for tamoxifen resistance. AIB1-expression in the presumable resistant (CBC after prior tamoxifen) and naïve setting (CBC without prior tamoxifen) is compared and correlated to prognosis after CBC.}}, author = {{Alkner, Sara and Bendahl, Pär-Ola and Ehinger, Anna and Lövgren, Kristina and Rydén, Lisa and Fernö, Mårten}}, issn = {{1932-6203}}, language = {{eng}}, number = {{3}}, publisher = {{Public Library of Science (PLoS)}}, series = {{PLoS ONE}}, title = {{Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.}}, url = {{http://dx.doi.org/10.1371/journal.pone.0150977}}, doi = {{10.1371/journal.pone.0150977}}, volume = {{11}}, year = {{2016}}, }